Abciximab Does Not Inhibit the Increase of Thrombin Generation Produced in Platelet-Rich Plasma In Vitro by Sodium Arachidonate or Tissue Factor

Abstract

Aspirin and platelet membrane glycoprotein (GP) IIb/IIIa blockers are currently used for acute coronary events, and in percutaneous coronary intervention for preventing further coronary outcomes, because they inhibit platelet function. Aspirin also inhibits thrombin generation (TG) in platelet-rich plasma (PRP) activated by sodium arachidonate (AA). The effect of the platelet membrane GP IIb-IIIa (integrin α_IIbβ₃) blocker abciximab on thrombin generation was studied in vitro using PRP. Thirty healthy volunteers taking no medication, and 28 volunteers who had taken aspirin (160 mg/day for 3-4 days), were included in the protocol. Control or in vivo aspirinated PRP, stimulated or not by AA or tissue factor (TF), was investigated for the inhibitory effect of abciximab pre-incubated for 3 minutes. AA and TF added in vitro activated non-aspirinated PRP: lag-time (LT) and time to peak (TTP) were significantly shortened. Peak TG (PTG) and endogenous thrombin potential (ETG) were increased by AA but not TF; thus, AA seems to be more efficient than TF for TG in this system. Abciximab added in vitro to non-activated, non-aspirinated PRP had no effect on LT, TTP, or ETP, but caused a decrease in PTG that was not statistically significant. Abciximab (3 or 4 μg/mL) added in vitro to AA or TF-activated, non-aspirinated PRP produced no effect on TG, although in aspirinated platelets both LT and time to peak were prolonged. AA as well as TF added in vitro to PRP or in vivo aspirinated PRP increased TG, although AA seems to be more efficient in our assay system. Abciximab, which affects nonaspirinated, nonactivated PRP weakly, has no effect on AA or TF in activated control PRP or in vivo aspirinated PRP.

Keywords

Abciximab Platelet aggregation Thrombingeneration

References

Hennekens CH , Dyken ML , Fuster V. Aspirin as a therapeutic agent in cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2751.

AntithromboticTrialists’ Collaboration . Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71.

Goldstein RE , Andrews M , Hall J , et al. for the Multicenter Myocardial Research Group . Marked reduction in long-term cardiac deaths with aspirin after a coronary event. J Am Coll Cardiol 1996;28:326.

Marcus AJ , Broekman MJ , Weksler BB , et al. Platelet, endothelial cells, and the thrombotic process. In: Herman AG , Vanhoutte PM , Denolin H , Goossens A , eds. Cardiovascular Pharmacology of the Prostaglandins. New York: Raven Press, 1982:125.

Kessels H , Béguin S , Andree H , et al. Measurement of thrombin generation in whole blood. The effect of heparin and aspirin. Thromb Haemost 1994;72:78.

Altman R , Scazziota A , Rouvier J , et al. Effect of sodium arachidonate on thrombin generation through platelet activation—inhibitory effect of aspirin. Thromb Haemost 2000;54:1109.

Ammar T , Scudder LE , Coller BS . In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614.

Reverter JC , Béguin S , Kessels H , et al. Inhibition of platelet-mediated tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and ‘clinical restenosis’. J Clin Invest 1996;98:863.

Coller BS , Lang D , Scudder LE . Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997;95:860.

10.

Béguin S , Lindhout T , Hemker HC . The effect of trace amount of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989;61:25.

11.

Ambrose JA , Hawkey M , Badimon JJ , et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol 2000;86:150.

12.

Wallen NH , Ladjevardi M. Influence of low-and high-dose aspirin treatment on thrombin generation in whole blood. Thromb Res 1998;92:189.

13.

Levy JH , Kelley A. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonists c7E3 Fab on the activated clotting time. Circulation 1997;96:3793.

14.

Byzova TV , Plow EF . Networking in the hemostatic system. Integrin αIIb/β3 binds prothrombin and influences its activation. J Biol Chem 1997;272:27183.

15.

Rota S , Flynn PD , Wareham NJ , et al.

Platelet phospholipid-dependent thrombin generation altered by acute myocardial infarction or aspirin?

Thromb Res 1996;83:329.

16.

Butenas S , Cawthern KM , Van’t Veer C , et al. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001;97:2314.

17.

Schneider DJ , Baumann PQ , Holmes MB , et al. Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin. Thromb Haemost 2001;85:309.

18.

Du XP , Plow EF , Frelinger AL , et al. Ligands “activate” integrin αIIb/β3 (platelet GPIIb/IIIa). Cell 1991;65:409.

19.

Peter K , Schwarz M , Ylänne J , et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIb/β3) inhibitors. Blood 1998;92:3240.

20.

Topol EJ , Byzova TV , Plow EF . Platelet GPIIb-IIIa blockers. Lancet 1999;353:227.

21.

Cox D. Methods for monitoring platelet function. Am Heart J 1998;135:S160.

22.

Jennings LK , White MM . Expression of ligand-induced binding site on glycoprotein IIb/IIIa complexes and the effect of various inhibitors. Am Heart J 1998;135:S179.

23.

Smith JB , Silver MJ . Prostaglandin synthesis by platelets and its biological significance. In: Gordon JL ed. Platelets in Biology and Pathology. Amsterdam: North-Holland Publishing 1979:331.

24.

Butenas S , Branda RF , Van’t Veer C , et al. Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 2001;86:660.

25.

Bahit MC , Granger CB , Wallentin L. Persistence of the prothrombotic state after acute coronary syndromes: Implications for treatment. Am Heart J 2002;143:205.

26.

Merlini PA , Repetto A , Lombardi A , et al. Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy. Circulation 2002;105:928.

27.

Mak KH . Effect of abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation. Circulation 2002;106:e57.

28.

Mak KH , Lee LH , Wong A , et al. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction. Am J Cardiol 2002;89:930.

29.

Mehta SR , Yusuf S. Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003;41(Suppl S):79S.

30.

Ottervanger JP , Armstrong P , Barnathan ES , et al. GUSTO IV-ACS Investigators. Long-term results after the glyco-protein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV—Acute Coronary Syndrome) Trial. Circulation 2003;107:437.

31.

Topol EJ , Easton D , Harrington RA , et al. Blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion trial investigators randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399.